S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in

Arbutus Biopharma Stock Forecast, Price & News

-0.50 (-13.74 %)
(As of 03/4/2021 12:00 AM ET)
Today's Range
Now: $3.14
50-Day Range
MA: $4.07
52-Week Range
Now: $3.14
Volume4.42 million shs
Average Volume3.12 million shs
Market Capitalization$266.61 million
P/E RatioN/A
Dividend YieldN/A
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with standard of care therapies, and in combination with each other. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Arbutus Biopharma logo


Recap: Arbutus Biopharma Q4 Earnings
March 4, 2021 |  benzinga.com
Arbutus Biopharma Corp. to Host Earnings Call
March 4, 2021 |  finance.yahoo.com
Earnings Preview: Arbutus Biopharma
March 3, 2021 |  finance.yahoo.com
ABUS Feb 2021 5.000 call
January 26, 2021 |  uk.finance.yahoo.com
ABUS Feb 2021 7.500 call
January 23, 2021 |  uk.finance.yahoo.com
ABUS Jan 2021 10.000 put
January 13, 2021 |  uk.finance.yahoo.com
Is ABUS A Good Stock To Buy Now?
December 12, 2020 |  finance.yahoo.com
ABUS Dec 2020 10.000 put
November 29, 2020 |  au.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ABUS
Year FoundedN/A



Sales & Book Value

Annual Sales$6.01 million
Book Value($1.00) per share


Net Income$-153,720,000.00
Net Margins-1,163.48%


Market Cap$266.61 million
Next Earnings Date5/6/2021 (Estimated)


Overall MarketRank

1.36 out of 5 stars

Medical Sector

674th out of 1,969 stocks

Pharmaceutical Preparations Industry

324th out of 772 stocks

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
-0.50 (-13.74 %)
(As of 03/4/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABUS News and Ratings via Email

Sign-up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions

Is Arbutus Biopharma a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arbutus Biopharma stock.
View analyst ratings for Arbutus Biopharma
or view top-rated stocks.

What stocks does MarketBeat like better than Arbutus Biopharma?

Wall Street analysts have given Arbutus Biopharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arbutus Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Arbutus Biopharma?

Arbutus Biopharma saw a decline in short interest in the month of February. As of February 12th, there was short interest totaling 2,550,000 shares, a decline of 20.1% from the January 28th total of 3,190,000 shares. Based on an average daily trading volume, of 3,970,000 shares, the days-to-cover ratio is currently 0.6 days.
View Arbutus Biopharma's Short Interest

When is Arbutus Biopharma's next earnings date?

Arbutus Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Arbutus Biopharma

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Co. (NASDAQ:ABUS) announced its quarterly earnings results on Tuesday, November, 10th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.05. The biopharmaceutical company had revenue of $1.52 million for the quarter, compared to analyst estimates of $1.81 million.
View Arbutus Biopharma's earnings history

How has Arbutus Biopharma's stock price been impacted by Coronavirus?

Arbutus Biopharma's stock was trading at $2.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ABUS stock has increased by 21.7% and is now trading at $3.14.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ABUS?

7 equities research analysts have issued twelve-month price objectives for Arbutus Biopharma's shares. Their forecasts range from $4.00 to $10.00. On average, they expect Arbutus Biopharma's share price to reach $6.29 in the next twelve months. This suggests a possible upside of 100.2% from the stock's current price.
View analysts' price targets for Arbutus Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Arbutus Biopharma's key executives?

Arbutus Biopharma's management team includes the following people:
  • Mr. William H. Collier, Pres, CEO & Director (Age 61, Pay $542.14k)
  • Mr. David C. Hastings, CFO & Chief Accounting Officer (Age 60, Pay $551.14k)
  • Dr. Michael J. Sofia, Chief Scientific Officer (Age 63, Pay $567.24k)
  • Pam Murphy, Investor Relations Consultant
  • Dr. Elizabeth Howard, Exec. VP, Gen. Counsel & Chief Compliance Officer (Age 67)
  • Dr. Gaston Picchio Ph.D., Chief Devel. Officer (Age 58)
  • Mr. Michael J. McElhaugh, Chief Bus. Officer (Age 47)
  • Mr. R. Hector Mackay-Dunn B.A., L.L.B., Q.C., J.D., Q.C, Sec. (Age 70)

What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO?

6 employees have rated Arbutus Biopharma CEO Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among Arbutus Biopharma's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Arbutus Biopharma's key competitors?

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (2.14%), Morgan Stanley (1.68%), Hudson Bay Capital Management LP (0.85%), Renaissance Technologies LLC (0.52%), ExodusPoint Capital Management LP (0.14%) and Northern Trust Corp (0.13%).
View institutional ownership trends for Arbutus Biopharma

Which institutional investors are selling Arbutus Biopharma stock?

ABUS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Charles Schwab Investment Management Inc., Northern Trust Corp, LMR Partners LLP, and ETF Managers Group LLC.
View insider buying and selling activity for Arbutus Biopharma
or view top insider-selling stocks.

Which institutional investors are buying Arbutus Biopharma stock?

ABUS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, ExodusPoint Capital Management LP, Virtu Financial LLC, Citigroup Inc., Bank of New York Mellon Corp, One68 Global Capital LLC, and Creative Planning.
View insider buying and selling activity for Arbutus Biopharma
or or view top insider-buying stocks.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $3.14.

How much money does Arbutus Biopharma make?

Arbutus Biopharma has a market capitalization of $266.61 million and generates $6.01 million in revenue each year. The biopharmaceutical company earns $-153,720,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis.

How many employees does Arbutus Biopharma have?

Arbutus Biopharma employs 78 workers across the globe.

What is Arbutus Biopharma's official website?

The official website for Arbutus Biopharma is www.arbutusbio.com.

Where are Arbutus Biopharma's headquarters?

Arbutus Biopharma is headquartered at 701 VETERANS CIRCLE, WARMINSTER PA, 18974.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The biopharmaceutical company can be reached via phone at 267-469-0914 or via email at [email protected]

This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.